Background Anticoagulation is recommended for hypertrophic cardiomyopathy (HCM) with
nonvalvular atrial fibrillation (NVAF) according to European and American guidelines …

Background: The prognostic effect of concomitant hypertrophic cardiomyopathy (HCM) on
adverse events in patients with atrial fibrillation (AF) has not been evaluated in a multicenter …

Background There have been no prior nationwide reports on the prevalence of hypertrophic
cardiomyopathy (HCM) among patients suffering from atrial fibrillation (AF). It is also unclear …

Context HCM is commonly associated with AF. Current guidelines for AF management omit
detailed advice for HCM because of a lack of clinical prediction tools that estimate the risk of …

Current treatment guidelines recommend anticoagulation for hypertrophic cardiomyopathy
(HCM) with atrial fibrillation (AF) regardless of the CHA 2 DS 2-VASc score. As aging and …

Data on the risk of ischemic stroke and systemic embolism (iSSE) events in patients with
nonvalvular atrial fibrillation (NVAF), a CHA 2 DS 2-VASc score of≤ 1, hypertrophic …

Aims Atrial fibrillation (AF) and thrombo‐embolism (TE) are associated with reduced survival
in hypertrophic cardiomyopathy (HCM), but the absolute risk of TE in patients with and …

In 1958, Donald Teare first described the pathology of asymmetric hypertrophy of the heart.
Teare, who worked as a pathologist at St George's hospital in London, reported on eight …

Among the various non-ischaemic primary myocardial diseases recognized in humans, the
most common is hypertrophic cardiomyopathy (HCM). Though first recognized more than 60 …

Background Accumulation of risk factors could increase thromboembolic event rates in
patients with nonvalvular atrial fibrillation (NVAF). To validate this hypothesis, a post hoc …